Skip to content

Application of Opioid-free Laryngeal Mask Ventilation General Anesthesia in Transurethral Ureteroscopy Laser Lithotripsy

Application of Opioid-free Laryngeal Mask Ventilation General Anesthesia in Transurethral Ureteroscopy Laser Lithotripsy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500110351
Enrollment
Unknown
Registered
2025-10-13
Start date
2025-10-13
Completion date
Unknown
Last updated
2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary calculus

Interventions

Part I: Esketamine Group:To explore the median effective dose of esketamine when combined with propofol during the anesthesia induction for laryngeal mask insertion during transurethral ureteroscopic
if the rating of laryngeal mask insertion was 3 or 4, it indicated a failed laryngeal mask insertion, and it was recorded as a positive reaction. The dose for the next patient was increased by one gra
Part II: Esketamine Combined with Propofol Group (Group E):Group E was intravenously injected with esketamine ED95 (obtained in Part 1) and propofol at a dose of 2mg/kg
Part II: Sufentanil combined with Propofol Group (Group S):Group S was intravenously injected with sufentanil at 0.2-0.3µg/kg and propofol at 2mg/kg. The laryngeal mask is placed only after the patien

Sponsors

Beijing Friendship Hospital, Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.It is classified as Grade I to III by the American Society of Anesthesiologists. 2. Age: 18-65 years old; 3. Body mass index < 30 kg/m ²

Exclusion criteria

Exclusion criteria: 1. Those with a history of allergy to propofol or esketamine or allergic to anesthetic drugs; 2. Those with a history of severe heart, lung, brain, liver or kidney diseases; 3. Those with severe hypertension, glaucoma or elevated intracranial pressure; 4. Those with a history of central nervous system diseases, mental illnesses, psychological disorders, or abnormal preoperative cognitive functions; 5. Those who have been taking sedative-hypnotic drugs or sedative-analgesic drugs for a long time; 6. Patients with difficult airways, chronic obstructive pulmonary disease, acute upper respiratory tract infections, asthma attacks or acute severe laryngeal diseases; 7. Those who refuse to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Part 1: Negative reaction / Positive reaction;Part 2: QoR-15;

Secondary

MeasureTime frame
Part 1: MAP, HR and SpO2;Part 2: MAP,HR and SpO2;Part 2: ;

Countries

China

Contacts

Public ContactWang Haixia

Beijing Friendship Hospital, Affiliated to Capital Medical University

wanghaixia1221@126.com+86 188 0123 9620

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026